Zobrazeno 1 - 10
of 30
pro vyhledávání: '"M Gail Murphy"'
Autor:
Rebecca L. Blanchard, John Palcza, Jan de Hoon, Kristien Van Dyck, Inge De Lepeleire, William S. Denney, Adrianna Gipson, Steve Vermeersch, Tae H. Han, M. Gail Murphy, Chi-Chung Li, William P. Kennedy, Marleen Depré
Publikováno v:
British Journal of Clinical Pharmacology. 79:831-837
Aims Calcitonin gene related peptide (CGRP) receptor antagonists are effective acute migraine treatments. A capsaicin-induced dermal vasodilatation (CIDV) model has been developed to provide target-engagement information in healthy volunteers. In the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b28b6a5e409e96cba6a08f8587cc077
https://doi.org/10.1111/bcp.12547
https://doi.org/10.1111/bcp.12547
Autor:
Christopher Lines, M. Gail Murphy, Chantal Mahon, John J. Renger, Hong Sun, John A. Wagner, Kate Mostoller, W. Joseph Herring, Catherine MacLeod, Gary G. Kay, Lingling Han, Valerie Schulz, Junshui Ma, Kevin R. Brown, Laura B. Rosen
Publikováno v:
The Journal of Clinical Pharmacology. 53:1294-1302
Histaminergic neurons are regulators of the sleep-wake cycle. We evaluated the alerting effects of MK-7288 (10, 20 mg), a novel histamine-3 receptor inverse agonist (H3RIA), along with modafinil (200 mg), a standard treatment, in a randomized, double
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::691bde734118828ca575e167420b3290
https://doi.org/10.1002/jcph.182
https://doi.org/10.1002/jcph.182
Autor:
Maureen Ho, Daniel Tatosian, Craig R. Shadle, M. Gail Murphy, Yang Liu, Robert A. Blum, Susie Xiujiang Li
Publikováno v:
Clinical pharmacology in drug development. 1(3)
Fosaprepitant dimeglumine, a lyophilized prodrug, is rapidly converted to aprepitant, a substance P/neurokinin 1 (NK1 ) receptor antagonist. Intravenous (IV) fosaprepitant and oral aprepitant are used in combination with other antiemetics to prevent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::048165a79fb7a5ae9777c29e1df01038
https://pubmed.ncbi.nlm.nih.gov/27121336
https://pubmed.ncbi.nlm.nih.gov/27121336
Autor:
Rebecca L. Blanchard, Marleen Depré, Jan de Hoon, M. Gail Murphy, Bart Van der Schueren, John Palcza, Inge De Lepeleire, Anne Van Hecken
Publikováno v:
British Journal of Clinical Pharmacology. 71:708-717
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Telcagepant (MK-0974, Merck & Co., Inc.), an oral calcitonin gene-related peptide (CGRP) antagonist, is effective in treating acute migraine headache. Although CGRP receptor antagonists seem devoid of dire
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd8d7b57cb4ad347f34af9d09e1201a7
https://doi.org/10.1111/j.1365-2125.2010.03869.x
https://doi.org/10.1111/j.1365-2125.2010.03869.x
Autor:
Ashley Martucci, Rebecca L. Blanchard, Deborah Panebianco, Maria Gutierrez, M. Gail Murphy, Christopher Lines, John Palcza, Cynthia Miller-Stein, Ronda K. Rippley, Tae H. Han
Publikováno v:
Archives of Drug Information. 3:55-62
Introduction. Telcagepant (MK-0974) is a novel, orally active and selective CGRP receptor antagonist being investigated for acute treatment of migraine. Early clinical data suggested greater than dose proportional increases in exposure following oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed0c16d39fb665034ea14ab29bad4bc3
https://doi.org/10.1111/j.1753-5174.2010.00031.x
https://doi.org/10.1111/j.1753-5174.2010.00031.x
Autor:
M. Gail Murphy, Howard E. Greenberg, Anup K. Majumdar, Walter K. Kraft, Matthew P. Braun, Dennis C. Dean, Keith Gottesdiener, Kevin J. Petty, S. Aubrey Stoch, Margaret Fedgchin, Jack Valentine, Deborah Panebianco, Cynthia Gargano, Edward Pequignot
Publikováno v:
Cancer Chemotherapy and Pharmacology. 67:1313-1321
Because glucocorticoids and the neurokinin-1 receptor antagonist aprepitant influence CYP3A4 activity, this study assessed whether aprepitant added to a 5-HT3 antagonist and glucocorticoid would affect CYP3A4 induction. In this double-blind, 2-period
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3be1f6da7adb2feae4e9c6db5bbb8fa5
https://doi.org/10.1007/s00280-010-1421-y
https://doi.org/10.1007/s00280-010-1421-y
Autor:
Debbie Panebianco, Kristien Van Dyck, Kenneth R. Hande, Anup K. Majumdar, Keith Gottesdiener, Veronique Cocquyt, Simon Van Belle, Marina De Smet, Tuli Ahmed, Margaret Fedgchin, Peter Nygren, Kevin J. Petty, M. Gail Murphy
Publikováno v:
Cancer Chemotherapy and Pharmacology. 55:609-616
Aprepitant is a selective neurokinin-1 receptor antagonist that is effective for the prevention of nausea and vomiting caused by highly emetogenic chemotherapy. In vitro, aprepitant is a moderate inhibitor of the CYP3A4 enzyme, which is involved in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85e1d8174dbca46a7cbc9464b6926691
https://doi.org/10.1007/s00280-004-0946-3
https://doi.org/10.1007/s00280-004-0946-3
Autor:
Ann O. Scheimann, Kuang C. Yeh, Roy Eisenhandler, Deborah Panebianco, John Baier, James D. Marshall, Gregory L. Kearns, M. Gail Murphy, Laura P. James, Larissa Wenning, Ling Zhong, Jeffrey L. Blumer
Publikováno v:
Clinical Pharmacokinetics. 44:395-406
Although famotidine pharmacokinetics are similar in adults and children older than 1 year of age, they differ in neonates owing to developmental immaturity in renal function. Little is currently known about the pharmacokinetics of famotidine in infan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f619340e713a703b6b9013423918ff29
https://doi.org/10.2165/00003088-200544040-00004
https://doi.org/10.2165/00003088-200544040-00004
Autor:
D. Ronald Goldwater, Michael R. Goldberg, Kevin J. Petty, Michael Hesney, Christopher Lines, Marian Iwamoto, Anup K. Majumdar, Paul J. Deutsch, Deborah Panebianco, Cynthia Gargano, M. Gail Murphy, Jacqueline B. McCrea, Robert A. Blum, Keith Gottesdiener
Publikováno v:
Clinical Pharmacology & Therapeutics. 74:17-24
Background Aprepitant is a neurokinin1 receptor antagonist that, in combination with a corticosteroid and a 5-hydroxytryptamine3 receptor antagonist, has been shown to be very effective in the prevention of chemotherapy-induced nausea and vomiting. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07bf8ef092d698298aec0d5f70b98ebf
https://doi.org/10.1016/s0009-9236(03)00066-3
https://doi.org/10.1016/s0009-9236(03)00066-3
Autor:
Michael Hesney, Walter K. Kraft, John Busillo, Kevin M. Gottesdiener, Christian D. Lates, Robert A. Blum, Howard E. Greenberg, Kevin J. Petty, M. Gail Murphy, Scott A. Waldman, Anup K. Majumdar, Sandi Van Buren, Michael R. Goldberg, Laura H. Orlowski, Carolyn M. Hustad, Jacqueline B. McCrea, Deborah Panebianco
Publikováno v:
Clinical Therapeutics. 25:1407-1419
Background: The neurokinin-1-receptor antagonist aprepitant, when given in combination with a corticosteroid and a 5-hydroxytryptamine type 3 (5-HT 3 )-receptor antagonist, has been shown to be effective for the prevention of acute and delated chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa947d2b436ccb38857b9ee4c0ad30e
https://doi.org/10.1016/s0149-2918(03)80128-5
https://doi.org/10.1016/s0149-2918(03)80128-5